Giant platelet disorder in a patient with type 2B von Willebrand's disease
โ Scribed by Moll, Stephan; Lazarowski, Alicia Rico; White, Gilbert C.
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 292 KB
- Volume
- 57
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
โฆ Synopsis
While patients with type 2B von Willebrand's disease often exhibit thrombocytopenia, platelet morphology is typically normal. We describe a 44-year-old Jamaican man with thrombocytopenia and a history of bleeding, who had giant platelets on his peripheral blood film. Functional studies and von Willebrand factor gene sequencing showed him to have type 2B von Willebrand's disease with a heterozygous point mutation resulting in a V553M (V1316M in the new von Willebrand factor gene mutation nomenclature) amino acid substitution. Family studies showed one of his two sisters to have an ill-defined giant-platelet-syndrome with mild thrombocytopenia, but not von Willebrand's disease, indicating that the association of giant platelets and von Willebrand's disease in our patient was most likely coincidental. This report describes the rare concurrence of two uncommon disorders. It also demonstrates how the thrombocytopenia of type 2B von Willebrand's disease can be misdiagnosed as ITP, leading to unnecessary and potentially harmful therapeutic interventions.
๐ SIMILAR VOLUMES
## Abstract P selectin is a component of endothelial WiebelโPalade body membrane and platelet alpha granule membrane. Patients with von Willebrand disease (VWD) have low plasma von Willebrand factor (VWF). To examine the relationship between plasma P selectin and VWF, both were measured by ELISA in
The PFA-100โข is a new platelet function analyzer which uses whole blood and high shear stress blood flow to simulate primary hemostasis and assess platelet function. A small volume of blood is introduced into a disposable cartridge, and forced through a capillary tube. Platelet adhesion and aggregat
DDAVP is effective treatment in most types of von Willebrand's disease; however, in type 28 von Willebrand's disease the use of DDAVP has been contraindicated due to DDAVPinduced thrombocytopenla. Several reports have confirmed the thrombocytopenic effects of DDAVP and the presence of circulating pl